Pharmaceutical Executive March 3, 2025
Miranda Schmalfuhs

In this part of his Pharmaceutical Executive Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, identifies strategies that pharmaceutical companies and digital health platforms can employ to navigate a potential drop in demand due to tariff-induced increased costs.

In this Pharmaceutical Executive Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, discusses the impact of tariffs on the pharmaceutical industry, highlighting that tariffs will initially affect pharmaceutical companies, particularly those dealing with branded medications and generics. He notes that tariffs could lead to strategic supply chain changes, including potential US manufacturing shifts. Digital health platforms like UpScriptHealth aim to reduce friction and costs in healthcare, potentially offsetting tariff impacts. Ax emphasizes the importance of telehealth in ensuring medication availability...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Conferences / Podcast, Pharma, Pharma / Biotech, Trends
Pharma Pulse 3/3/25: Will Tariffs Affect Branded Drug Prices? Pharmacists' Role in Medical Cannabis Counseling and Patient Education & more
Biotech startup pulls in $187M to make ‘multi-payload’ ADCs
Pharma’s Role in Ensuring Patient Access to Trustworthy Health Insights
AbbVie Enters Obesity Field, Paying $350M for Amylin Receptor Agonist Already in the Clinic
State Licensing Spotlight - Prescription medical device manufacturers & distributors: Regulatory considerations applicable to medical devices versus drugs

Share This Article